MP50-15 ASSOCIATION BETWEEN WEIGHT GAIN AND SARCOPENIC OBESITY IN PATIENTS WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY

2012. Half the patients had localized disease and were referred for curative intended radiation, whereas the remaining patients had disseminated disease. ADT was given as LHRH agonists, LHRH antagonists, or orchiectomy. We collected blood samples, questionnaire, performed DXA scan and bone scintigraphy prior to initiating ADT and during the following two years of ADT. The study was approved by the local ethical committee. None of the patients had received prior androgen deprivation nor osteoporosis treatment. RESULTS: A total of 105 individuals were included. The mean age of the participants was 70 (range 53-91, SD 6.3) years. The median PSA level was 30.5 (range 1-5714) mg/L. The median Gleason score was 7 (range 5-10, SD 1.1). A total of 50 patients had localized prostate cancer; the remaining 55 patients had disseminated disease. The prevalence of osteoporosis was 10% and the prevalence of osteopenia was 58% prior to initiating ADT, and after two years of ADT it rose to 22% and 57%, respectively. In multivariate analysis smoking and presence of disseminated disease were significantly associated with an increased risk of osteoporosis, whereas a high body mass index was significantly associated with a decreased risk of osteoporosis. CONCLUSIONS: Osteoporosis was present among patients with prostate cancer and evolved rapidly during two years of ADT. Further awareness regarding osteoporosis and bone health in prostate cancer patients is needed and we recommend that patients with prostate cancer are DXA scanned prior to and during ADT.